TheTechno Optimist.

Rezanecel (NRTX-1001)UCB—Rezanecel holds an 89% median cut in disabling seizures at low dose in updated data at AAN 2026Rezanecel (NRTX-1001)UCB—NRTX-1001 seizure cuts deepen past the first year in long-term data at the American Epilepsy Society meetingRezanecel (NRTX-1001)UCB—UCB agrees to buy Neurona Therapeutics and its epilepsy cell therapy for up to $1.15BRezanecel (NRTX-1001)UCB—UCB completes its acquisition of Neurona Therapeutics

Rezanecel (NRTX-1001)

by UCBBE

Give people with drug-resistant temporal lobe epilepsy lasting seizure control from one procedure, without removing brain tissue as today's surgery does.

PilotStage 3 of 5

Phase 1/2 in 31 people; UCB plans the sham-controlled EPIC Phase 3 for the first half of 2027.

Updated 2 Jun 2026Checked 11 Oct0 updates this week

Milestones

Next · First patient in EPIC Phase 3
  1. First patient dosed in Phase 1/2 trial2022Complete.
  2. FDA RMAT designationJun 2024Complete.
  3. Phase 3 plan set after FDA talks; $102M financingApr 2025Complete.
  4. EMA PRIME designationOct 2025Complete.
  5. UCB completes Neurona acquisition2 Jun 2026Complete.
  6. First patient in EPIC Phase 3Target 2027+24 mooriginally 2025Current milestone.

Most important updates

Upcoming

  1. 2027First patient in EPIC Phase 3+24 mooriginally 2025 (next)
Primer